Despite Cures Boost, Lingering Appropriations Means FDA Device Funding Still An Unknown For 2017
With the president's signature of the 21st Century Cures Act, US FDA has $20m in FY 2017 to begin carrying out a multitude of reforms in the law. Meanwhile, the regular budget appropriated by Congress will remain at 2016 levels through April. But as of Dec. 14, device center director Jeff Shuren said he did not know the amounts specifically that would go to his center. And now FDA supporters wonder if the Cures dollars will be tapped to do regular agency work.
You may also be interested in...
Rep. Shimkus, Author Of 'Cures' Device Provisions, Joins Exodus Of Republicans Retiring In 2020 From US House
Illinois Rep. John Shimkus, a well-known pro-medtech industry bill sponsor, announced on 30 August his plans for a January 2020 retirement. He joins at least 15 Republican House members who recently said they are also ending their Capitol Hill careers, leaving six vacancies on the US House Energy and Commerce and Ways and Means panels prior to the 2020 elections.
Congressional health committees will spend time in 2017 focusing on oversight of agencies' implementation of the 21st Century Cures Act and the Medicare Authorization and CHIP Reauthorization Act, as well as five-year reauthorization of the medical device and prescription drug user fee acts.
The Senate approved the same 21st Century Cures bill passed by the House last week on a 94-5 tally; the bill is expected to be quickly signed by President Obama. Provisions for extra dollars for FDA in the bill means that even with a plan by Congress to adopt a continuing resolution this week freezing FDA funding until April 28, the agency can rely on an additional $20 million set aside for it in Cures in the new year.